Earlier today we issued a news release, as required by Irish Law, confirming that we have been approached by Pfizer and are in preliminary friendly discussions regarding a potential business combination transaction. We also confirmed that, under any potential scenario, we remain strongly committed to completing the proposed divestment of our global generics business to Teva in the first quarter of 2016. You can read our full press release on www.Allergan.com.